While “Cluster 3” cell lines expressed genes commonly found in the intrinsic gene list preferentially expressed in basal-like primary BC (e.g. LCN, RARRES1, CLDN1, KRT17; Figure 1B) [20], “Cluster 2” was characterised by a higher abundance of CAV1, a marker for the basal-like phenotype of sporadic and hereditary breast cancers [21], and the lymphangiogenic factor VEGFC, a potential therapeutic target for triple-negative BCs [22] (Figure 1C). This evidence concerns the gene CLDN1 and breast cancer.